A Phase 1/2 interventional study of Inotuzumab Ozogamicin in Acute Lymphocytic Leukemia, sponsored by Leland Metheny. Recruiting at 7 sites in United States. Open to participants aged 16 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-10.
Sponsored by Leland Metheny · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing Inotuzumab Ozogamicin in Precursor Cell Lymphoblastic Leukemia-Lymphoma — 8 open to participants now, 11 under way, none of them phase 3. Inotuzumab Ozogamicin · Precursor Cell Lymphoblastic Leukemia-Lymphoma.
Among the 20 studies testing Inotuzumab Ozogamicin in Precursor Cell Lymphoblastic Leukemia-Lymphoma, this one is the 11th largest by planned enrollment, is one of 3 that started in 2017, is the only one in phase 1/2, reaches primary completion later than 4 of the 10 other live ones, and was the 6th registered.
2,586 studies on the registry are indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma; 471 are open to participants now.
Browse Precursor Cell Lymphoblastic Leukemia-Lymphoma studies →8 of the 20 studies testing Inotuzumab Ozogamicin in Precursor Cell Lymphoblastic Leukemia-Lymphoma are open now, in 12 countries. Recruiting first, the newest first:
The First Affiliated Hospital of Soochow University · Sites in China
Ages 15+
Institute of Hematology & Blood Diseases Hospital, China · Sites in China
Ages 18+
Institute of Hematology & Blood Diseases Hospital, China · Sites in China
Ages 18+
Pfizer · Sites in Austria, Belgium, Czechia and 12 more countries
Ages 1–17
University of Chicago · Sites in United States
Ages 18+
By country, each count listing its studies:
Inotuzumab Ozogamicin: first FDA approval 2017 (BESPONSA), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 369 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 96 (26%) set no upper age limit and 257 (70%) stop at 75 or younger; 247 take children under 18; 29 take healthy volunteers.
This study: 16 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 16 · Phase 3 1 · Phase 4 2
First in 2010; this study’s year is marked. 3 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 44 is close to the median of 40 across 1,953 interventional studies indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma.
Median enrollment 47 across the 20 interventional studies. Of the 9 that completed or were terminated, 7 (78%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 20 have an industry lead sponsor. The 10 most frequent:
Leland Metheny is the lead sponsor of 6 studies on the registry; 2 are open to participants now.
Leland Metheny has 3 studies filed under Precursor Cell Lymphoblastic Leukemia-Lymphoma — fewer than ten, so there is no comparison to draw.
3 of the studies testing Inotuzumab Ozogamicin in Precursor Cell Lymphoblastic Leukemia-Lymphoma that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03104491Leland MethenyInotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia | 2026-11 |
| NCT06387121Institute of Hematology & Blood Diseases Hospital, ChinaEfficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALL | 2026-12-01 |
| NCT03441061M.D. Anderson Cancer CenterInotuzumab Ozogamicin in Treating Patients With B-cell Acute Lymphocytic Leukemia With Positive Minimal Residual Disease | 2027-02-28 |
Add all 3 to your calendar (.ics) → With an account.
Among the 20 studies testing Inotuzumab Ozogamicin in Precursor Cell Lymphoblastic Leukemia-Lymphoma, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study has two phases, Phase I and Phase II. The main goal of the Phase I portion of this research study is to see what doses post-transplant inotuzumab ozogamicin can safely be given to subjects without having too many side effects.
The Phase II portion of this study is to see what side effects are seen with medication after transplant.
Inotuzumab ozogamicin is a combination of an antibody and chemotherapy which has been shown to have significant activity against relapsed/refractory acute lymphocytic leukemia (ALL).
Inotuzumab ozogamicin is considered experimental in this study.
Study Design This is a Phase I/II study of inotuzumab ozogamicin for the treatment of patients who underwent allogeneic transplantation for ALL and have a high risk of relapse. The Phase I portion of this study will be a 3+3 dose escalation trial. This is followed by a phase 2 cohort at the recommended Phase 2 dose (RP2D). Participants will receive study treatment up to 4 cycles until relapse of disease, unacceptable toxicity, or death, whichever occurs first
Phase I: Inotuzumab Ozogamicin Dosing Escalation Subjects will be assessed for safety and tolerability (including adverse events, serious adverse events, and clinical/laboratory assessments) using a continuous monitoring approach.
Phase II: Inotuzumab Ozogamicin Subjects will be assessed for safety and tolerability (including adverse events, serious adverse events, and clinical/laboratory assessments) using a continuous monitoring approach. In order to be included in the safety profile endpoint review, subjects must have received at least of 1 cycle of treatment.
Primary Objective
Phase I: To define a post hematopoietic stem cell transplantation maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of inotuzumab ozogamicin.
Phase II: To assess the efficacy of inotuzumab ozogamicin as measured by diseasefree survival (DFS) at one year.
Secondary Objective(s)
Phase I:
Phase II:
Inclusion Criteria:
Phase 1 Inclusion Criteria
Patients who have/are either:
Transplanted in hematologic first complete remission with evidence of minimal residual disease within 45 days of allogeneic transplantation
---Pre- or Post-Transplant Minimal Residual Disease defined by:
----Any detectable ALL (by flow cytometry, cytogenetics, or PCR techniques) as per clinical indication.
Phase 2 Inclusion Criteria
Patients who have/are either:
Transplanted in hematologic first complete remission with evidence of minimal residual disease within 45 days of allogeneic transplantation
---Post-Transplant Minimal Residual Disease defined by:
----Any detectable ALL (by flow cytometry, cytogenetics, or PCR techniques) as per clinical indication.
Phase 1 and 2 Exclusion Criteria:
Patients with inadequate organ function as defined by:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GVHD (graft-versus-host disease)
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Phase I: A maximum of 4 cycles will be allowed and doses will be adjusted in 0.1mg/m2 increments using a dose escalation scale depending on tolerability. Total range of dose levels for participants is 0.1-0.6mg/m\^2. Phase II: Participants will be enrolled until all Phase I participants have been followed and assessed for toxicity for at least 4 weeks after the fourth treatment dose of inotuzumab ozogamicin or 4 weeks after the participant goes off treatment, whichever comes first. Doses to be administered will be determined in the phase I portion of the study. The recommended phase 2 dose is 0.3mg/m2. Repeat cycles every 28 days for up to 4 cycles
Drug: Inotuzumab Ozogamicin
Inotuzumab ozogamicin, IV, 28 day cycles Phase 1 dosages: Dose Level -2 (0.1 mg/m\^2) Dose Level -1 (0.2 mg/m\^2) Dose Level 0 (0.3 mg/m\^2) Dose Level 1 (0.4 mg/m\^2) Dose Level 2 (0.5 mg/m\^2) Dose Level 3 (0.6 mg/m\^2)
Phase I MTD
Defined post hematopoietic stem cell transplantation MTD
Time frame: Up to 112 days (16 weeks)
Phase I DLTs
Frequency of DLTs during the first two cycles in ALL-participants
Time frame: Up to 112 days (16 weeks)
Phase II Median DFS
Efficacy as measured by phase II DFS at one year, estimated using Kaplan-Meier, reported as median and 2-sided 80% and 95% Confidence Interval (CI) DFS is defined as "Time from date of first dose to the date of disease progression (ie,objective progression, relapse from CR/CRi), or death due to any cause, whichever occurs first (including post-study treatment follow-up disease assessments)". Difference in time-to-event endpoints will be tested using a 1-sided log-rank test at a significance level of 0.10 In Phase II, the null hypothesis of H0: DFS at 1-year ≤ 55% versus the alternative hypothesis of Ha: DFS at 1-year ≥ 75% using 1-sided alpha of 10% will be tested
Time frame: At 3 months after initial treatment
Phase II Median DFS
Efficacy as measured by phase II DFS at one year, estimated using Kaplan-Meier, reported as median and 2-sided 80% and 95% Confidence Interval (CI) DFS is defined as "Time from date of first dose to the date of disease progression (ie,objective progression, relapse from CR/CRi), or death due to any cause, whichever occurs first (including post-study treatment follow-up disease assessments)". Difference in time-to-event endpoints will be tested using a 1-sided log-rank test at a significance level of 0.10 In Phase II, the null hypothesis of H0: DFS at 1-year ≤ 55% versus the alternative hypothesis of Ha: DFS at 1-year ≥ 75% using 1-sided alpha of 10% will be tested
Time frame: At 6 months after initial treatment
Phase II Median DFS
Efficacy as measured by phase II DFS at one year, estimated using Kaplan-Meier, reported as median and 2-sided 80% and 95% Confidence Interval (CI) DFS is defined as "Time from date of first dose to the date of disease progression (ie,objective progression, relapse from CR/CRi), or death due to any cause, whichever occurs first (including post-study treatment follow-up disease assessments)". Difference in time-to-event endpoints will be tested using a 1-sided log-rank test at a significance level of 0.10 In Phase II, the null hypothesis of H0: DFS at 1-year ≤ 55% versus the alternative hypothesis of Ha: DFS at 1-year ≥ 75% using 1-sided alpha of 10% will be tested
Time frame: At 9 months after initial treatment
Phase II Median DFS
Efficacy as measured by phase II DFS at one year, estimated using Kaplan-Meier, reported as median and 2-sided 80% and 95% Confidence Interval (CI) DFS is defined as "Time from date of first dose to the date of disease progression (ie,objective progression, relapse from CR/CRi), or death due to any cause, whichever occurs first (including post-study treatment follow-up disease assessments)". Difference in time-to-event endpoints will be tested using a 1-sided log-rank test at a significance level of 0.10 In Phase II, the null hypothesis of H0: DFS at 1-year ≤ 55% versus the alternative hypothesis of Ha: DFS at 1-year ≥ 75% using 1-sided alpha of 10% will be tested
Time frame: At 1 year after initial treatment
Phase II Median DFS
Efficacy as measured by phase II DFS at one year, estimated using Kaplan-Meier, reported as median and 2-sided 80% and 95% Confidence Interval (CI) DFS is defined as "Time from date of first dose to the date of disease progression (ie,objective progression, relapse from CR/CRi), or death due to any cause, whichever occurs first (including post-study treatment follow-up disease assessments)". Difference in time-to-event endpoints will be tested using a 1-sided log-rank test at a significance level of 0.10 In Phase II, the null hypothesis of H0: DFS at 1-year ≤ 55% versus the alternative hypothesis of Ha: DFS at 1-year ≥ 75% using 1-sided alpha of 10% will be tested
Time frame: Post first dose of inotuzumab ozogamicin
Phase I Median DFS
Efficacy as measured by phase I DFS at one year. Estimated using Kaplan-Meier, reported as median and 2-sided 80% and 95% Confidence Interval (CI) DFS is defined as "Time from date of first dose to the date of disease progression (ie,objective progression, relapse from CR/CRi), or death due to any cause, whichever occurs first (including post-study treatment follow-up disease assessments)" Difference in time-to-event endpoints will be tested using a 1-sided log-rank test at a significance level of 0.10
Time frame: At 3 months after initial treatment
Phase I Median DFS
Efficacy as measured by phase I DFS at one year. Estimated using Kaplan-Meier, reported as median and 2-sided 80% and 95% Confidence Interval (CI) DFS is defined as "Time from date of first dose to the date of disease progression (ie,objective progression, relapse from CR/CRi), or death due to any cause, whichever occurs first (including post-study treatment follow-up disease assessments)" Difference in time-to-event endpoints will be tested using a 1-sided log-rank test at a significance level of 0.10
Time frame: At 6 months after initial treatment
Phase I Median DFS
Efficacy as measured by phase I DFS at one year. Estimated using Kaplan-Meier, reported as median and 2-sided 80% and 95% Confidence Interval (CI) DFS is defined as "Time from date of first dose to the date of disease progression (ie,objective progression, relapse from CR/CRi), or death due to any cause, whichever occurs first (including post-study treatment follow-up disease assessments)" Difference in time-to-event endpoints will be tested using a 1-sided log-rank test at a significance level of 0.10
Time frame: At 9 months after initial treatment
Phase I Median DFS
Efficacy as measured by phase I DFS at one year. Estimated using Kaplan-Meier, reported as median and 2-sided 80% and 95% Confidence Interval (CI) DFS is defined as "Time from date of first dose to the date of disease progression (ie,objective progression, relapse from CR/CRi), or death due to any cause, whichever occurs first (including post-study treatment follow-up disease assessments)" Difference in time-to-event endpoints will be tested using a 1-sided log-rank test at a significance level of 0.10
Time frame: At 1 year after initial treatment
Phase I Median DFS
Efficacy as measured by phase I DFS at one year. Estimated using Kaplan-Meier, reported as median and 2-sided 80% and 95% Confidence Interval (CI) DFS is defined as "Time from date of first dose to the date of disease progression (ie,objective progression, relapse from CR/CRi), or death due to any cause, whichever occurs first (including post-study treatment follow-up disease assessments)" Difference in time-to-event endpoints will be tested using a 1-sided log-rank test at a significance level of 0.10
Time frame: Post first dose of inotuzumab ozogamicin on Day 1, Cycle 1, where cycle length is 28 days
Phase I NRM
Phase I NRM, defined as time from date of first dose to death due to any cause without prior relapse. Criteria used: For ALL, evidence of disease in the blood or bone marrow (flow cytometry or PCR). Reported as Cumulative Incidence and 2-sided 80% CI and 2-sided 95% CI
Time frame: At 3 months after initial treatment
Phase I NRM
Phase I NRM, defined as time from date of first dose to death due to any cause without prior relapse. Criteria used: For ALL, evidence of disease in the blood or bone marrow (flow cytometry or PCR). Reported as Cumulative Incidence and 2-sided 80% CI and 2-sided 95% CI
Time frame: At 6 months after initial treatment
Phase I NRM
Phase I NRM, defined as time from date of first dose to death due to any cause without prior relapse. Criteria used: For ALL, evidence of disease in the blood or bone marrow (flow cytometry or PCR). Reported as Cumulative Incidence and 2-sided 80% CI and 2-sided 95% CI
Time frame: At 9 months after initial treatment
Phase I NRM
Phase I NRM, defined as time from date of first dose to death due to any cause without prior relapse. Criteria used: For ALL, evidence of disease in the blood or bone marrow (flow cytometry or PCR). Reported as Cumulative Incidence and 2-sided 80% CI and 2-sided 95% CI
Time frame: At 1 year after initial treatment
Phase I NRM
Phase I NRM , defined as time from date of first dose to death due to any cause without prior relapse. Criteria used: For ALL, evidence of disease in the blood or bone marrow (flow cytometry or PCR). Reported as Cumulative Incidence and 2-sided 80% CI and 2-sided 95% CI
Time frame: Post first dose of inotuzumab ozogamicin on Day 1, Cycle 1, where cycle length is 28 days
Phase I Relapse
Phase I relapse rate, defined as time from date of first dose to the date of first relapse. Reported as Cumulative Incidence and 2-sided 80% CI and 2-sided 95% CI
Time frame: At 3 months after initial treatment
Phase I Relapse
Phase I relapse rate, defined as time from date of first dose to the date of first relapse. Reported as Cumulative Incidence and 2-sided 80% CI and 2-sided 95% CI
Time frame: At 6 months after initial treatment
Phase I Relapse
Phase I relapse rate, defined as time from date of first dose to the date of first relapse. Reported as Cumulative Incidence and 2-sided 80% CI and 2-sided 95% CI
Time frame: At 9 months after initial treatment
Phase I Relapse
Phase I relapse rate, defined as time from date of first dose to the date of first relapse. Reported as Cumulative Incidence and 2-sided 80% CI and 2-sided 95% CI
Time frame: At 1 year after initial treatment
Phase I Relapse
Phase I relapse rate, defined as time from date of first dose to the date of first relapse. Reported as Cumulative Incidence and 2-sided 80% CI and 2-sided 95% CI
Time frame: Post first dose of inotuzumab ozogamicin on Day 1, Cycle 1, where cycle length is 28 days
Phase I Relapse-related mortality
Phase I Relapse-related mortality, defined time from date of first dose to death due to any cause with prior relapse Reported as Cumulative Incidence and 2-sided 80% CI and 2-sided 95% CI
Time frame: At 3 months after initial treatment
Phase I Relapse-related mortality
Phase I Relapse-related mortality, defined time from date of first dose to death due to any cause with prior relapse Reported as Cumulative Incidence and 2-sided 80% CI and 2-sided 95% CI
Time frame: At 6 months after initial treatment
Phase I Relapse-related mortality
Phase I Relapse-related mortality, defined time from date of first dose to death due to any cause with prior relapse Reported as Cumulative Incidence and 2-sided 80% CI and 2-sided 95% CI
Time frame: At 9 months after initial treatment
Phase I Relapse-related mortality
Phase I Relapse-related mortality, defined time from date of first dose to death due to any cause with prior relapse Reported as Cumulative Incidence and 2-sided 80% CI and 2-sided 95% CI
Time frame: At 1 year after initial treatment
Phase I Relapse-related mortality
Phase I Relapse-related mortality, defined time from date of first dose to death due to any cause with prior relapse Reported as Cumulative Incidence and 2-sided 80% CI and 2-sided 95% CI
Time frame: Post first dose of inotuzumab ozogamicin on Day 1, Cycle 1, where cycle length is 28 days
Phase I Median OS
Phase I OS, defined from time from date of first dose to death due to any cause, estimated using Kaplan-Meier, reported as median and 95% CI Difference in time-to-event endpoints will be tested using a 1-sided log-rank test at a significance level of 0.10
Time frame: At 3 months after initial treatment
Phase I Median OS
Phase I OS, defined from time from date of first dose to death due to any cause, estimated using Kaplan-Meier, reported as median and 95% CI Difference in time-to-event endpoints will be tested using a 1-sided log-rank test at a significance level of 0.10
Time frame: At 6 months after initial treatment
Phase I Median OS
Phase I OS, defined from time from date of first dose to death due to any cause, estimated using Kaplan-Meier, reported as median and 95% CI Difference in time-to-event endpoints will be tested using a 1-sided log-rank test at a significance level of 0.10
Time frame: At 9 months after initial treatment
Phase I Median OS
Phase I OS, defined from time from date of first dose to death due to any cause, estimated using Kaplan-Meier, reported as median and 95% CI Difference in time-to-event endpoints will be tested using a 1-sided log-rank test at a significance level of 0.10
Time frame: At 1 year after initial treatment
Phase I Median OS
Phase I OS, defined from time from date of first dose to death due to any cause, estimated using Kaplan-Meier, reported as median and 95% CI Difference in time-to-event endpoints will be tested using a 1-sided log-rank test at a significance level of 0.10
Time frame: Post first dose of inotuzumab ozogamicin on Day 1, Cycle 1, where cycle length is 28 days
Phase I Incidence of myeloid toxicity
Number of patients who develop myeloid toxicity while on study, defined as grade of anemia, neutropenia and thrombocytopenia CTCAE 4
Time frame: At 1 year
Phase I Incidence of secondary graft failure
Number of patients who develop secondary graft failure while on study, defined as: Either cytopenias after initial engraftment (ANC \<500/µL), with (a) donor chimerism of less than 5% or (b) falling donor chimerism with intervention such as second transplant or donor lymphocyte infusion (DLI) or (c) patient death due to cytopenias, and fall in donor chimerism, even if chimerism was \>5%. Exclusion criteria for diagnosis of GF were (a) disease relapse (b) graft versus host disease or (c) other causes of cytopenias such as, viral infections, or drug induced
Time frame: At 1 year
Phase I incidence of veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS)
Safety profile of intervention as measured by incidence of VOD/SOS disease in the phase I portion of the study, defined as the occurrence of 2 of the following 3 clinical criteria: * Total serum bilirubin level \>34 μmol/L (\>2.0 mg/dL). * An increase in liver size from baseline or development of right upper quadrant pain of liver origin. * Sudden weight gain \>2.5% during any 72-hour period after infusion of investigational product because of fluid accumulation or development of ascites.
Time frame: At 1 year
Phase I rate of VOD/SOS - number of participants affected
Safety profile of intervention as measured by number of participants affected by VOD/SOS disease in the phase I portion of the study, defined as the occurrence of 2 of the following 3 clinical criteria: * Total serum bilirubin level \>34 μmol/L (\>2.0 mg/dL). * An increase in liver size from baseline or development of right upper quadrant pain of liver origin. * Sudden weight gain \>2.5% during any 72-hour period after infusion of investigational product because of fluid accumulation or development of ascites.
Time frame: At 1 year
Phase I - Percent of participants with grade 3 + AE/SAEs
Phase I safety profile of intervention as measured by percent of participants with grade 3 + AE/SAEs
Time frame: At 1 year
Phase II Non-relapse mortality (NRM)
Phase II Non-relapse mortality (NRM), defined as time from date of first dose to death due to any cause without prior relapse. Reported as Cumulative Incidence and 2-sided 80% CI and 2-sided 95% CI
Time frame: At 3 months after initial treatment
Phase II Relapse
Phase II relapse rate, defined as time from date of first dose to the date of first relapse. Reported as Cumulative Incidence and 2-sided 80% CI and 2-sided 95% CI
Time frame: At 6 months after initial treatment
Phase II Relapse
Phase II relapse rate, defined as time from date of first dose to the date of first relapse. Reported as Cumulative Incidence and 2-sided 80% CI and 2-sided 95% CI
Time frame: At 9 months after initial treatment
Phase II Relapse-related mortality
Phase II Relapse-related mortality, defined time from date of first dose to death due to any cause with prior relapse Reported as Cumulative Incidence and 2-sided 80% CI and 2-sided 95% CI
Time frame: At 1 year after initial treatment
Phase II Relapse-related mortality
Phase II Relapse-related mortality, defined time from date of first dose to death due to any cause with prior relapse Reported as Cumulative Incidence and 2-sided 80% CI and 2-sided 95% CI
Time frame: Post first dose of inotuzumab ozogamicin on Day 1, Cycle 1, where cycle length is 28 days
Phase II Median OS
Phase II OS, defined from time from date of first dose to death due to any cause, estimated using Kaplan-Meier, reported as median and 95% CI Difference in time-to-event endpoints will be tested using a 1-sided log-rank test at a significance level of 0.10
Time frame: At 3 months after initial treatment
Phase II Median OS
Phase II OS, defined from time from date of first dose to death due to any cause, estimated using Kaplan-Meier, reported as median and 95% CI Difference in time-to-event endpoints will be tested using a 1-sided log-rank test at a significance level of 0.10
Time frame: At 6 months after initial treatment
Phase II Median OS
Phase II OS, defined from time from date of first dose to death due to any cause, estimated using Kaplan-Meier, reported as median and 95% CI Difference in time-to-event endpoints will be tested using a 1-sided log-rank test at a significance level of 0.10
Time frame: At 9 months after initial treatment
Phase II Median OS
Phase II OS, defined from time from date of first dose to death due to any cause, estimated using Kaplan-Meier, reported as median and 95% CI Difference in time-to-event endpoints will be tested using a 1-sided log-rank test at a significance level of 0.10
Time frame: At 1 year after initial treatment
Phase II Median OS
Phase II OS, defined from time from date of first dose to death due to any cause, estimated using Kaplan-Meier, reported as median and 95% CI Difference in time-to-event endpoints will be tested using a 1-sided log-rank test at a significance level of 0.10
Time frame: Post first dose of inotuzumab ozogamicin on Day 1, Cycle 1, where cycle length is 28 days
Phase II Response Rate
Defined as the proportion of patients with a best overall response of eradicating MRD at the time each patient discontinues treatment with Inotuzumab Ozogamicin
Time frame: At 3 months after initial treatment
Phase II Response Rate
Defined as the proportion of patients with a best overall response of eradicating MRD at the time each patient discontinues treatment with Inotuzumab Ozogamicin
Time frame: At 6 months after initial treatment
Phase II Response Rate
Defined as the proportion of patients with a best overall response of eradicating MRD at the time each patient discontinues treatment with Inotuzumab Ozogamicin
Time frame: At 9 months after initial treatment
Phase II Response Rate
Defined as the proportion of patients with a best overall response of eradicating MRD at the time each patient discontinues treatment with Inotuzumab Ozogamicin
Time frame: At 1 year after initial treatment
Phase II Response Rate
Defined as the proportion of patients with a best overall response of eradicating MRD at the time each patient discontinues treatment with Inotuzumab Ozogamicin
Time frame: Post first dose of inotuzumab ozogamicin on Day 1, Cycle 1, where cycle length is 28 days
Phase II Incidence of myeloid toxicity
Number of patients who develop myeloid toxicity while on study, defined as grade of anemia, neutropenia and thrombocytopenia CTCAE 4
Time frame: At 1 year
Phase II Incidence of secondary graft failure
Number of patients who develop secondary graft failure while on study, defined as: Either cytopenias after initial engraftment (ANC \<500/µL), with (a) donor chimerism of less than 5% or (b) falling donor chimerism with intervention such as second transplant or donor lymphocyte infusion (DLI) or (c) patient death due to cytopenias, and fall in donor chimerism, even if chimerism was \>5%. Exclusion criteria for diagnosis of GF were (a) disease relapse (b) graft versus host disease or (c) other causes of cytopenias such as, viral infections, or drug induced
Time frame: At 1 year after initial treatment
Phase I incidence of VOD/SOS
Safety profile of intervention as measured by incidence of VOD/SOS disease in the phase I portion of the study, defined as the occurrence of 2 of the following 3 clinical criteria: * Total serum bilirubin level \>34 μmol/L (\>2.0 mg/dL). * An increase in liver size from baseline or development of right upper quadrant pain of liver origin. * Sudden weight gain \>2.5% during any 72-hour period after infusion of investigational product because of fluid accumulation or development of ascites.
Time frame: At 1 year
Phase II rate of VOD/SOS - number of participants affected
Safety profile of intervention as measured by number of participants affected by VOD/SOS disease in the phase I portion of the study, defined as the occurrence of 2 of the following 3 clinical criteria: * Total serum bilirubin level \>34 μmol/L (\>2.0 mg/dL). * An increase in liver size from baseline or development of right upper quadrant pain of liver origin. * Sudden weight gain \>2.5% during any 72-hour period after infusion of investigational product because of fluid accumulation or development of ascites.
Time frame: At 1 year
Phase II pharmacokinetic (PK) parameters - Cmax
Phase II PK parameter Cmax is maximum concentration. Descriptive statistics (n, mean, SD, %CV, median, minimum, maximum, geometric mean, its associated geometric %CV) of inotuzumab ozogamicin serum concentrations will be presented in tabular form by cycle, day, and nominal time for the PK concentration analysis population.
Time frame: At Cycle 1 Day 1 (C1D1) after 0 hours (each cycle is 28 days)
Phase II pharmacokinetic (PK) parameters - Cmax
Phase II PK parameter Cmax is maximum concentration. Descriptive statistics (n, mean, SD, %CV, median, minimum, maximum, geometric mean, its associated geometric %CV) of inotuzumab ozogamicin serum concentrations will be presented in tabular form by cycle, day, and nominal time for the PK concentration analysis population.
Time frame: At Cycle 1 Day 1 (C1D1) after 1 hour (each cycle is 28 days)
Phase II pharmacokinetic (PK) parameters - Cmax
Phase II PK parameter Cmax is maximum concentration. Descriptive statistics (n, mean, SD, %CV, median, minimum, maximum, geometric mean, its associated geometric %CV) of inotuzumab ozogamicin serum concentrations will be presented in tabular form by cycle, day, and nominal time for the PK concentration analysis population.
Time frame: At Cycle 1 Day 1 (C1D1) after 4 hours (each cycle is 28 days)
Phase II pharmacokinetic (PK) parameters - Cmax
Phase II PK parameter Cmax is maximum concentration. Descriptive statistics (n, mean, SD, %CV, median, minimum, maximum, geometric mean, its associated geometric %CV) of inotuzumab ozogamicin serum concentrations will be presented in tabular form by cycle, day, and nominal time for the PK concentration analysis population.
Time frame: At Cycle 1 Day 7 (C1D7) (each cycle is 28 days)
Phase II pharmacokinetic (PK) parameters - Cmax
Phase II PK parameter Cmax is maximum concentration. Descriptive statistics (n, mean, SD, %CV, median, minimum, maximum, geometric mean, its associated geometric %CV) of inotuzumab ozogamicin serum concentrations will be presented in tabular form by cycle, day, and nominal time for the PK concentration analysis population.
Time frame: At Cycle 2 Day 1 (C2D1) after 0 hours (each cycle is 28 days)
Phase II pharmacokinetic (PK) parameters - Cmax
Phase II PK parameter Cmax is maximum concentration. Descriptive statistics (n, mean, SD, %CV, median, minimum, maximum, geometric mean, its associated geometric %CV) of inotuzumab ozogamicin serum concentrations will be presented in tabular form by cycle, day, and nominal time for the PK concentration analysis population.
Time frame: At Cycle 2 Day 1 (C2D1) after 1 hour (each cycle is 28 days)
Phase II pharmacokinetic (PK) parameters - Cmax
Phase II PK parameter Cmax is maximum concentration. Descriptive statistics (n, mean, SD, %CV, median, minimum, maximum, geometric mean, its associated geometric %CV) of inotuzumab ozogamicin serum concentrations will be presented in tabular form by cycle, day, and nominal time for the PK concentration analysis population.
Time frame: At Cycle 4 Day 1 (C4D1) after 0 hours (each cycle is 28 days)
Phase II pharmacokinetic (PK) parameters - Cmax
Phase II PK parameter Cmax is maximum concentration. Descriptive statistics (n, mean, SD, %CV, median, minimum, maximum, geometric mean, its associated geometric %CV) of inotuzumab ozogamicin serum concentrations will be presented in tabular form by cycle, day, and nominal time for the PK concentration analysis population.
Time frame: At Cycle 4 Day 1 (C4D1) after 1 hour (each cycle is 28 days)
Phase II pharmacokinetic (PK) parameters - Ctrough
Phase II PK parameter Ctrough is lowest concertration of Inotuzumab in the blood.Descriptive statistics (n, mean, SD, %CV, median, minimum, maximum, geometric mean, its associated geometric %CV) of inotuzumab ozogamicin serum concentrations will be presented in tabular form by cycle, day, and nominal time for the PK concentration analysis population.
Time frame: At Cycle 1 Day 1 (C1D1) after 0 hours (each cycle is 28 days)
Phase II pharmacokinetic (PK) parameters - Ctrough
Phase II PK parameter Ctrough is lowest concertration of Inotuzumab in the blood.Descriptive statistics (n, mean, SD, %CV, median, minimum, maximum, geometric mean, its associated geometric %CV) of inotuzumab ozogamicin serum concentrations will be presented in tabular form by cycle, day, and nominal time for the PK concentration analysis population.
Time frame: At Cycle1 Day 1 (C1D1) after 1 hour (each cycle is 28 days)
Phase II pharmacokinetic (PK) parameters - Ctrough
Phase II PK parameter Ctrough is lowest concertration of Inotuzumab in the blood.Descriptive statistics (n, mean, SD, %CV, median, minimum, maximum, geometric mean, its associated geometric %CV) of inotuzumab ozogamicin serum concentrations will be presented in tabular form by cycle, day, and nominal time for the PK concentration analysis population.
Time frame: At Cycle1 Day 1 (C1D1) after 4 hours (each cycle is 28 days)
Phase II pharmacokinetic (PK) parameters - Ctrough
Phase II PK parameter Ctrough is lowest concertration of Inotuzumab in the blood.Descriptive statistics (n, mean, SD, %CV, median, minimum, maximum, geometric mean, its associated geometric %CV) of inotuzumab ozogamicin serum concentrations will be presented in tabular form by cycle, day, and nominal time for the PK concentration analysis population.
Time frame: At Cycle 1 Day 7 (C1D7) (each cycle is 28 days)
Phase II pharmacokinetic (PK) parameters - Ctrough
Phase II PK parameter Ctrough is lowest concertration of Inotuzumab in the blood.Descriptive statistics (n, mean, SD, %CV, median, minimum, maximum, geometric mean, its associated geometric %CV) of inotuzumab ozogamicin serum concentrations will be presented in tabular form by cycle, day, and nominal time for the PK concentration analysis population.
Time frame: At Cycle 2 Day 1 (C2D1) after 0 hours (each cycle is 28 days)
Phase II pharmacokinetic (PK) parameters - Ctrough
Phase II PK parameter Ctrough is lowest concertration of Inotuzumab in the blood.Descriptive statistics (n, mean, SD, %CV, median, minimum, maximum, geometric mean, its associated geometric %CV) of inotuzumab ozogamicin serum concentrations will be presented in tabular form by cycle, day, and nominal time for the PK concentration analysis population.
Time frame: At Cycle 2 Day 1 (C2D1) after 1 hour (each cycle is 28 days)
Phase II pharmacokinetic (PK) parameters - Ctrough
Phase II PK parameter Ctrough is lowest concertration of Inotuzumab in the blood.Descriptive statistics (n, mean, SD, %CV, median, minimum, maximum, geometric mean, its associated geometric %CV) of inotuzumab ozogamicin serum concentrations will be presented in tabular form by cycle, day, and nominal time for the PK concentration analysis population.
Time frame: At Cycle 4 Day 1 (C4D1) after 0 hours (each cycle is 28 days)
Phase II pharmacokinetic (PK) parameters - Ctrough
Phase II PK parameter Ctrough is lowest concertration of Inotuzumab in the blood.Descriptive statistics (n, mean, SD, %CV, median, minimum, maximum, geometric mean, its associated geometric %CV) of inotuzumab ozogamicin serum concentrations will be presented in tabular form by cycle, day, and nominal time for the PK concentration analysis population.
Time frame: At Cycle 4 Day 1 (C4D1) after 1 hour (each cycle is 28 days)
Not enrolling at this site.
Not enrolling at this site.
Not enrolling at this site.
Started Jul 2017 (actual). Primary completion is estimated for Nov 2026, 112 months after the start.
Of 81 non-industry phase 1/2 interventional studies under Precursor Cell Lymphoblastic Leukemia-Lymphoma, half reached primary completion within 75 months of starting (the median), counting those still running; a quarter within 57 and three quarters within 119. This study's planned 112 months is above that.
Counting every sponsor, half of 114 studies reached it within 79 months; a quarter within 56 and three quarters within 119.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Inotuzumab Ozogamicin
Precursor Cell Lymphoblastic Leukemia-Lymphoma →
Leland Metheny